Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Patellar

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Patellar. Displaying page 1 of 1.
    EudraCT Number: 2016-001262-28 Sponsor Protocol Number: MSC-TENDO-2015 Start Date*: 2017-08-21
    Sponsor Name:Institut de Terapia Regenerativa Tissular S.L. (ITRT)
    Full Title: Treatment of Refractory Patellar Tendinopathy with MSV *. Comparative study with P-PRP *MSV are bone marrow autologous mesenchymal stem cells, selected and cultured under Good manufacturing Practic...
    Medical condition: Patients diagnosed with patellar tendinopathy with a minimum of 4 months evolution and have presented two acute episodes, refractory to standard treatments present a gap equal or greater than 3 mm ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10034123 Patellar tendinitis LLT
    Population Age: Adults Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003587-36 Sponsor Protocol Number: 684/MODREC/15 Start Date*: 2016-04-13
    Sponsor Name:Directorate of Defence Rehabilitation
    Full Title: Chronic Tendinopathy: The Biomechanical Associations and EfFicacy of Injectable Therapy (BE FIT) Study
    Medical condition: Chronic degenerative Achilles and patella tendinopathy patients, with neovascularisation on USS, who have failed best practice rehabilitation including Eccentric Loading (EL), Heavy Slow Resistance...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10000433 Achilles tendinitis LLT
    18.1 100000004859 10034123 Patellar tendinitis LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-021957-38 Sponsor Protocol Number: B70720108785 Start Date*: 2010-10-29
    Sponsor Name:CHU Liège - Physical Medicine Service
    Full Title: Contribution à l’optimalisation du traitement des tendinopathies chroniques : injection de concentrés plaquettaires chez des patients présentant une tendinopathie rotulienne supérieure Optimizatio...
    Medical condition: Jumper's knee or patellar tendinopathy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004973-25 Sponsor Protocol Number: PIAS005/06 Start Date*: 2008-05-28
    Sponsor Name:Laboratoire Expanscience
    Full Title: Prospective multicentric open clinical study comparing the efficacy and safety of piascledine 300 plus standard treatment versus standard treatment only in patients with osteoarthritis of the knee
    Medical condition: Osteoarthritis of the knee
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-001782-18 Sponsor Protocol Number: MRZ 92579-0404/1 Start Date*: 2005-02-14
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Saftey and efficacy of two different doses of Neramexane mesylate as preemptive analgesic and add-on therapy to opioids in the management of postoperative pain. A randomised, double-blind, placebo-...
    Medical condition: Moderate to severe acute postoperative pain
    Disease: Version SOC Term Classification Code Term Level
    7.1 10054711 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-004921-33 Sponsor Protocol Number: R475-OA-1758 Start Date*: 2018-11-09
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients with Pain Due to Osteoarthritis of the Hip or Knee
    Medical condition: Pain due to osteoarthritis of the hip or knee
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10023476 Knee osteoarthritis LLT
    20.0 100000004859 10020108 Hips osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-001429-32 Sponsor Protocol Number: CACZ885D2201 Start Date*: 2012-03-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, open label, 24-month treatment study to establish the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of canakinumab (anti-IL-1 beta antibody) in patients with...
    Medical condition: Neonatal onset multisystem inflammatory disease (abbreviated NOMID, also known as chronic infantile neurologic cutaneous and articular syndrome or CINCA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10068850 Cryopyrin associated periodic syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-000300-42 Sponsor Protocol Number: 03AR0298 Start Date*: 2013-01-18
    Sponsor Name:National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    Full Title: A long-term outcome study with the IL-1 receptor antagonist Anakinra/Kineret® in patients with Neonatal onset multisystem inflammatory disease (Nomid/Cinca syndrome)
    Medical condition: neonatal onset multisystem inflammatory disease (NOMID/CINCA)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-003447-29 Sponsor Protocol Number: DAP-PEDBAC-11-02 Start Date*: 2013-06-11
    Sponsor Name:Cubist Pharmaceuticals, Inc.
    Full Title: A COMPARATIVE EVALUATION OF THE SAFETY AND EFFICACY OF DAPTOMYCIN VERSUS STANDARD OF CARE IN PEDIATRIC SUBJECTS TWO - SEVENTEEN YEARS OF AGE WITH BACTEREMIA CAUSED BY STAPHYLOCOCCUS AUREUS.
    Medical condition: Bacteremia caused by Staphylococcus Aureus.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10054637 Staphylococcal bacteremia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) HU (Completed) GR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-003490-15 Sponsor Protocol Number: CACZ885D2308 Start Date*: 2016-04-14
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: An Open-label, Efficacy and Safety Study of Canakinumab (Anti-interleukin-1β Monoclonal Antibody) Administered for 6 Months (24 Weeks) in Japanese Patients With the Following Cryopyrin-associated P...
    Medical condition: Cryopyrin-associated Periodic Syndromes Familial Cold Autoinflammatory Syndrome Muckle-Wells Syndrome Neonatal Onset Multisystem Inflammatory Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10064570 Familial cold autoinflammatory syndrome PT
    19.0 10010331 - Congenital, familial and genetic disorders 10064574 NOMID LLT
    19.0 10010331 - Congenital, familial and genetic disorders 10068850 Cryopyrin associated periodic syndrome PT
    19.0 10010331 - Congenital, familial and genetic disorders 10064569 Muckle-Wells syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001702-15 Sponsor Protocol Number: R475-OA-1688 Start Date*: 2018-03-05
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo And NSAID-Controlled Study To Evaluate The Efficacy And Safety Of Fasinumab In Patients With Pain Due To Osteoarthritis Of The Knee Or Hip
    Medical condition: Pain due to osteoarthritis of the knee or hip
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10023476 Knee osteoarthritis LLT
    20.0 100000004859 10020108 Hips osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) DE (Completed) EE (Completed) GB (GB - no longer in EU/EEA) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 18:16:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA